ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 285,86
-0,60%
Dow Jones
39 142,23
-1,33%
DAX
21 205,86
-0,52%
Brent Oil
67,075
0,00%
Bitcoin
84 979,78
0,07%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) Actualités

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KPTI
DateHeureSourceTitreSymboleSociété
14/04/202514h24Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KPTIKaryopharm Therapeutics Inc
14/04/202514h19Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KPTIKaryopharm Therapeutics Inc
14/04/202514h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
10/04/202523h23Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KPTIKaryopharm Therapeutics Inc
07/04/202522h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/04/202522h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/02/202522h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
24/02/202514h40PR Newswire (US)Karyopharm Announces 1-for-15 Reverse Stock SplitNASDAQ:KPTIKaryopharm Therapeutics Inc
19/02/202513h30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
12/02/202513h00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025NASDAQ:KPTIKaryopharm Therapeutics Inc
13/01/202514h30PR Newswire (US)Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 ObjectivesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/01/202523h07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/01/202513h00PR Newswire (US)Karyopharm Announces the Appointment of Lori Macomber as Chief Financial OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
09/12/202414h00PR Newswire (US)Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422h35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202413h00PR Newswire (US)Karyopharm Therapeutics Provides Endometrial Cancer Program UpdateNASDAQ:KPTIKaryopharm Therapeutics Inc
25/11/202413h00PR Newswire (US)Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
20/11/202422h05PR Newswire (US)Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
14/11/202422h22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202414h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413h47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413h30PR Newswire (US)Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202413h00PR Newswire (US)Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202412h30PR Newswire (US)Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202421h30PR Newswire (US)Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
03/09/202413h00PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/08/202413h30PR Newswire (US)Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
31/07/202422h05PR Newswire (US)Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
19/07/202422h07Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
20/06/202414h01Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Dernières Valeurs Consultées

COIN
OPCTBTC
Opacity
BMF
FROF37
FROF37 - 01/2037
BIT
S29068
Societe Generale Effekten
BIT
S28186
Societe Generale Effekten
USOTC
SKSUY
Sekisui Chemical (PK)
BIT
S28287
Societe Generale Effekten
AQSE
XGLD.GB
DB ETC
TG
A19QKQ
Telecom Italia
COIN
XYOEUR
XY Oracle
BIT
S32519
Societe Generale Effekten
BIT
F33440
Vontobel Financial Produ...
TG
A280F4
Teva Pharmaceutical Fina...
POLO
WSBUSDT
Wall Street Baby
BIT
P1H4O7
BNP Paribas Issuance
USOTC
LTHO
Legacy Technology (CE)
BIT
I06807
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces